EVENTS:   Best Equity Short Ideas Conference Call 12 - Zach Shannon/Corto Capital Advisors & Craig Huber/Huber Research Partners & Thomas Beevers /Forensic Alpha & Ed Steele/Iron Blue Financials & Bill Campbell/Paragon Intel - 12 Nov 25   Will AI Deflate the World? Macro Lessons from Three Industrial Revolutions and China - Manoj Pradhan/Talking Heads Macro - 13 Nov 25     ROADSHOWS: Forest Products Sector Equity and Commodity Research With Expertise in Distressed Debt - Kevin Mason /ERA Research   •   London   12 - 14 Nov 25       Buyside to Buyside Forum and Expert Calls across TMT, Consumer, Healthcare and Fintech - Andrew Peters /Revelare Partners   •   London   17 - 19 Nov 25       Fundamental US Healthcare Short Ideas - Dr Elliot Favus /Favus Institutional Research   •   London   17 - 19 Nov 25      

Fortnightly Publication Highlighting Latest Insights From IRF Providers

Company Research

Liquidity Risk Model: Best short candidates

Two Rivers Analytics

ChargePoint (CHPT) - Burns $400m annually, a figure which is rising fast. Expected to run through most of its cash balance by early to mid-2024. Forecasts expect sales to continue slowing. Not expected to breakeven until 2026.
Floor & Decor (FND) - Requires nearly immediate outside financing, primarily due to very high capex spending. Net debt $1.8bn (vs. $200m in 2018). Sales are expected to slow further during 2023.
Natera (NTRA) - Diagnostics company will run out of cash by Sep having burned $700m+ in the past year. Not expected to breakeven until at least 2028. Trades at 5x 2023 and 2024 sales.

Edition: 155

- 03 March, 2023


Natera (NTRA)

Healthcare

Gradient Analytics

New short thesis on this $10.8bn Mkt/Cap firm in the Diagnostics & Research industry - key points include: (1) Increased frequency of complaints about its billing practices. (2) Insurance providers have been reluctant to reimburse for microdeletion screening. (3) Disparate trends between receivables and deferred revenue signal deteriorating revenue quality. (4) NTRA may have pushed current-period expenses into the future. (5) Executives and directors have engaged in some unusual divestiture activity in recent periods. (6) Valuation metrics leave room for further downside.

Edition: 122

- 29 October, 2021